$144 Million

Oncopeptides AB

PIPE

Bookrunner, May 2020

Oncopeptides AB
Directed Share Issue

Oncopeptides is a clinical development pharmaceutical company focused on conducting anti-cancer research to develop treatments for the benefit of patients. Oncopeptides’ lead product candidate is Ygalo (melflufen), the first peptidase potentiated cytotoxic therapy intended for use in the treatment of multiple myeloma.